NASDAQ:DCTH

Delcath Systems Stock Insider Trading

Healthcare > Medical - Specialties

Buy DCTH

*Your capital is at risk

$10.33

-0.200 (-1.90%)

At Close: Jun 03, 2026

Delcath Systems Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be positive at 100.00. In total, the insiders bought 11.02M and sold 77.82K DCTH shares in the last 100 trades. The insider score can be negative despite buy/sell ratio being positive. The score focuses on the quality of the trades.

Insider Power (Last 100 transactions)	100.00
● Buy	11.02M shares
● Sell	77.82K shares
89% Buy Activity Moderate Positive Correlation
No Significant Signals No statistically significant buy or sell signals detected in recent insider data.

Historical Insider Trades

Date	Type	Person	Role	Amount
Feb 07, 2025 Buy	Stock Option (Right to Buy) A-Award	Rook Martha S. Chief Operating Officer	C-Suite Officer	113 000 Value: $1.84M
Feb 07, 2025 Buy	Stock Option (Right to Buy) A-Award	Muir Kevin Gm Interventional Oncology	Officer	113 000 Value: $1.84M
Feb 07, 2025 Buy	Stock Option (Right to Buy) A-Award	Pennell Sandra Chief Financial Officer	C-Suite Officer	113 000 Value: $1.84M
Dec 24, 2024 Buy	Common shares C-Conversion	Salamon Steven A J Director	Director	250 000 Value: $2.50M
Dec 24, 2024 Buy	Pre-funded Warrants M-Exempt	Salamon Steven A J Director	Director	603 954 Value: $6K
Dec 24, 2024 Buy	Pre-funded Warrants M-Exempt	Salamon Steven A J Director	Director	603 954 Value: $6K
Dec 24, 2024 Buy	Common shares C-Conversion	Salamon Steven A J Director	Director	250 000 Value: $2.50M
Dec 24, 2024 Buy	Common shares C-Conversion	Aharon Gil Director	Director	250 000 Value: $2.50M
Dec 24, 2024 Buy	Pre-funded Warrants M-Exempt	Aharon Gil Director	Director	603 954 Value: $6K
Dec 24, 2024 Buy	Common shares C-Conversion	Rosalind Advisors, Inc. Director	Director	250 000 Value: $2.50M
Dec 24, 2024 Buy	Pre-funded Warrants M-Exempt	Rosalind Advisors, Inc. Director	Director	603 954 Value: $6K
Dec 24, 2024 Buy	Pre-funded Warrants M-Exempt	Rosalind Advisors, Inc. Director	Director	603 954 Value: $6K
Dec 24, 2024 Buy	Common shares C-Conversion	Rosalind Advisors, Inc. Director	Director	250 000 Value: $2.50M
Dec 24, 2024 Buy	Pre-funded Warrants M-Exempt	Aharon Gil Director	Director	603 954 Value: $6K
Dec 24, 2024 Buy	Common shares C-Conversion	Aharon Gil Director	Director	250 000 Value: $2.50M
Oct 30, 2024 Buy	Tranche B warrants to purchase F-4 Preferred Stock M-Exempt	Aharon Gil Director	Director	500 Value: $500.0K
Oct 30, 2024 Sell	8% CONVERTIBLE NOTE H-ExpireLong	Aharon Gil Director	Director	0 Value: $0
Oct 30, 2024 Buy	Tranche B warrants to purchase F-4 Preferred Stock M-Exempt	Salamon Steven A J Director	Director	500 Value: $500.0K
Oct 30, 2024 Sell	8% CONVERTIBLE NOTE H-ExpireLong	Salamon Steven A J Director	Director	0 Value: $0
Oct 30, 2024 Buy	Tranche B warrants to purchase F-4 Preferred Stock M-Exempt	Rosalind Advisors, Inc. Director	Director	500 Value: $500.0K
Oct 30, 2024 Sell	8% CONVERTIBLE NOTE H-ExpireLong	Rosalind Advisors, Inc. Director	Director	0 Value: $0
Oct 30, 2024 Sell	8% CONVERTIBLE NOTE H-ExpireLong	Rosalind Advisors, Inc. Director	Director	0 Value: $0
Oct 30, 2024 Buy	Tranche B warrants to purchase F-4 Preferred Stock M-Exempt	Rosalind Advisors, Inc. Director	Director	500 Value: $500.0K
Oct 30, 2024 Sell	8% CONVERTIBLE NOTE H-ExpireLong	Salamon Steven A J Director	Director	0 Value: $0
Oct 30, 2024 Buy	Tranche B warrants to purchase F-4 Preferred Stock M-Exempt	Salamon Steven A J Director	Director	500 Value: $500.0K

About Insider Power

Insider Power is a proprietary algorithm developed by StockInvest.us to evaluate the significance of insider transactions. The calculation considers the size, type, and timing of transactions, as well as the insider’s role within the company.

It is important to note that, in general, there is little to no correlation between insider transactions and short-term stock price movements. In one of our studies, only 0.22%^* of stocks with insider activity showed a measurable correlation — and even then, it was unclear whether the effect was caused by insider actions or simply by the stock’s broader trend.

While our algorithms are designed to highlight potentially meaningful signals, these cannot be regarded as statistically significant on their own. Insider trading activity should therefore be seen as informative rather than as direct trading guidance. The Insider Power metric was created to present this information in a clearer and more accessible way, helping investors better understand the possible context of insider activity.

* October 6th, 2025 - Tested on 5562 stocks

ABOUT DELCATH SYSTEMS, INC.

Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan hydrochloride for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. Its clinical development program for HEPZATO is the FOCUS cli...

Read Full Profile Here